Due to its overexpression in multiple cancer types and its well-established role in tumor progression via the CXCR4/CXC12 axis, CXCR4 is another therapeutic target, with inhibitors such as plerixafor being used for autologous transplantation of bone marrow in patients with Non-Hodgkin’s lymphoma or multiple myeloma and as a chemosensitizer (208, 209). The gene discussed is CXCR4; the disease is non-Hodgkin lymphoma.